Novome Biotherapeutics is a biotech startup that specializes in engineering cell therapies to combat chronic diseases. The company operates in the healthcare market, specifically in the field of synthetic biology and microbiome therapeutics. Novome's unique approach involves the use of Genetically Engineered Microbial Medicines (GEMMs), which are microbes engineered to colonize the gut and perform specific therapeutic activities.

The company's business model revolves around the development and commercialization of these GEMMs. The microbes are designed to colonize the gut for an extended period, with their abundance maintained and adjusted through a daily dose of a prebiotic polysaccharide. This approach allows for sustained and effective therapies for chronic diseases.

Novome's primary clients are patients suffering from chronic diseases, who stand to benefit from their innovative therapies. The company generates revenue through the development, clinical testing, and eventual sale of these therapies.

Their lead program, NOV-001, has already demonstrated safety and controllable engraftment in a Phase 1 study involving healthy volunteers. This therapy is currently being studied further, indicating the company's progress in bringing its innovative solutions to market.

In summary, Novome Biotherapeutics is a pioneering biotech company that leverages synthetic biology to engineer cell therapies, offering a novel approach to treating chronic diseases.

Keywords: Biotech, Cell Therapies, Chronic Diseases, Synthetic Biology, Microbiome Therapeutics, Genetically Engineered Microbial Medicines (GEMMs), Prebiotic Polysaccharide, NOV-001, Stanford University, Colonization.